ArticleClinical cancer research : an official journal of the American Association for Cancer Research2014

Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.

Daniel W Bowles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.